Mitra Biotech raises ₹270 crores in seriec C funding

Must Read

President Ram Nath Kovind appoints new governor for Kerala, Telangana, Himachal Pradesh and Maharashtra

President Ram Nath Kovind appointed new governors for Maharashtra, Kerala, Telangana, Rajasthan, and Himachal Pradesh on Sunday. Former Union Minister Kalraj...

NRC list for Assam released; Fear looms as 19 lakh people face exclusion

NRC (National Register of Citizens) for Assam has been published at 10 am today. The final list excludes over...

Lateral Entry Era Begins as Union govt. appoints 9 professionals to Joint Secretary posts

The government has appointed its first batch of private professionals to the post of Joint Secretary in various ministries....

Bengaluru-based Mitra Biotech, Oncology Solution providing startup, has raised ₹270 crores ($40 million) in series C funding led by Maryland-based Northpond Ventures, along with the participation from existing investors, Accel Partners, Sequoia Capital, Sands Capital Ventures, RA Capital Management and Tata Capital. Mitra Biotech has raised around ₹520 crores ($76 million) in total after the completion of this funding.

The company intends to use the funds raised for the commercial expansion and completing the required data generation to get reimbursement coverage for a broad category for cancer indications.

Mitra Biotech is a global leader in oncology treatment and supporting more efficient and effective cancer drug development. It was founded by Mallik Sundaram and Pradip K Majumdar in 2010. The company already has a team of 150 employees, out of which 50 are based in the US, while the other 100 are in Bengaluru.

Mallik Sundaram, co-founder, President and Chief Executive Officer, Mitra Biotech, said, “The company is working on insurance coverage of CANscript for broad cancer indications for multiple classes of drugs in advanced settings,”.

Mitra’s CANscript is a unique diagnostic platform that helps in giving treatment response predictions. This can be used by the physicians and doctors to help them in selecting the most efficient and responsive drug for the treatment of tumors in patients. CANsript ranks the drugs by their efficiency in treating the tumors, thereby eliminating the most inefficient drugs. This will help the patients in a big way without having to keep looking for better drugs in the market.

Mitra Biotech has been helping other drug companies in developing better testing methods for their clinical trials. It also aims to feature in the Nasdaq’s list in the time frame of 2020-21.

“We are working with more than 15 companies and carrying out around 50 projects,” said Sundaram.

Mitra Biotech has partnered with some of the major to cancer care hospitals to further their drug treatment and testing studies. Healthcare Global (HCG) Group of Hospitals, Apollo Hospital-Delhi, and Fortis Hospital-Delhi are among some of its partners.


Please enter your comment!
Please enter your name here

- Advertisement -

Latest News

Injured Nadal pulls out of final two Laver Cup matches

Geneva, Sep 22 (IANS) US Open champion and tennis star Rafael Nadal withdrew from his matches at the Laver...

Congress, Rahul ‘playing politics’ on J&K, says Shah (Lead)

Mumbai, Sep 22 (IANS) Union Home Minister Amit Shah on Sunday attacked the Congress and its former President Rahul Gandhi in the issue of...

Chinmayanand case: In which both parties are culprits and victims

By Sanjeev Kumar Singh ChauhanShahjahanpur, Sep 22 (IANS) Call it the power of the ubiquitousness of technology. The rape and blackmail of the Shahjahanpur...

Carolina Marin caps comeback from injury with China Open win

Changzhou (China), Sep 22 (IANS) Olympic champion Carolina Marin on Sunday beat Taiwanese former world no.1 Tai Tzu Ying to win a second consecutive...

Modi to address Indian diaspora at ‘Howdy Modi!’

Houston, Sep 22 (IANS) Prime Minister Narendra Modi on Sunday would attend the mega 'Howdy Modi!' event being organised at the NRG stadium here...
- Advertisement -

More Articles Like This